Vaccine vexed; plus assessing Lilly’s Alzheimer’s data & PDUFA preview: a BioCentury podcast

March 16, 2021 1:28 AM UTC

The only thing that’s clear from the latest big Alzheimer’s readout is that the entrenched camps of amyloid believers and doubters will take predictably polarized views. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the data for Lilly’s donanemab along with the latest concerns over AstraZeneca’s COVID-19 vaccine, the biologics-heavy focus of the ongoing PDUFA negotiations, and what’s behind Takeda’s takeout of Maverick.

Editor in Chief Simone Fishburn sizes up the current controversy over the COVID vaccine from AstraZeneca plc (LSE:AZN; NASDAQ:AZN) after a handful of major EU nations hit pause on their vaccination programs deploying the product. EMA says it’s watching the situation, with a comment on next steps due late this week, while the U.K.’s MHRA and the company say they don’t see a signal...